1. Ginsenoside Rb1 attenuates age-associated vascular impairment by modulating the Gas6 pathway
- Author
-
Shiye Ke, Lin Wu, Min Wang, Dinghui Liu, Guangyao Shi, Jieming Zhu, and Xiaoxian Qian
- Subjects
ageing ,vascular calcification ,fibrosis ,growth arrest-specific protein 6 (gas6)/axl pathway ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Context Ginsenoside Rb1 (Rb1) exerts many beneficial effects and protects against cardiovascular disease. Objective To investigate whether Rb1 could attenuate age-related vascular impairment and identify the mechanism. Materials and methods Female C57BL/6J mice aged 2 and 18 months, randomly assigned to Young, Young + 20 mg/kg Rb1, Old + vehicle, Old + 10 mg/kg Rb1 and Old + 20 mg/kg Rb1 groups, were daily intraperitoneal injected with vehicle or Rb1 for 3 months. The thoracic aorta segments were used to inspect the endothelium-dependent vasorelaxation. Left thoracic aorta tissues were collected for histological or molecular expression analyses, including ageing-related proteins, markers relevant to calcification and fibrosis, and expression of Gas6/Axl. Results We found that in Old + vehicle group, the expression of senescence proteins and cellular adhesion molecules were significantly increased, with worse endothelium-dependent thoracic aorta relaxation (58.35% ± 2.50%) than in Young group (88.84% ± 1.20%). However, Rb1 treatment significantly decreased the expression levels of these proteins and preserved endothelium-dependent relaxation in aged mice. Moreover, Rb1 treatment also reduced calcium deposition, collagen deposition, and the protein expression levels of collagen I and collagen III in aged mice. Furthermore, we found that the downregulation of Gas6 protein expression by 41.72% and mRNA expression by 52.73% in aged mice compared with young mice was abrogated by Rb1 treatment. But there was no significant difference on Axl expression among the groups. Conclusions Our study confirms that Rb1 could ameliorate vascular injury, suggesting that Rb1 might be a potential anti-ageing related vascular impairment agent.
- Published
- 2021
- Full Text
- View/download PDF